Navigate to Other Sector


Healthcare Newsletter – October 2018

Milestone Month for Breast Cancer Therapeutics - Pfizer's NCE approval & combination drugs
Medical Devices - FDA approves LVAD as Destination Therapy for patients ineligible for heart transplants
First Antiviral for Influenza with a Novel MoA Approved in 20 Years - Commercial success hinges on indication expansion
Focus on healthcare cost optimization drives transformational consolidation - CVS-Aetna gets DoJ approval
Advancements in vaccines infrastructure& FDA Gardasil supplemental approval
Biosimilar markets - EU opportunity expands while market access concerns continue to plague US
Health Tech - First Augemented Reality medical system for Microsoft Hololens gets FDA clearance

Discussion — No responses

Show Buttons
Hide Buttons